Skip to main content
Premium Trial:

Request an Annual Quote

Tripos, AstraZeneca, WorldFusion, Ariadne, Boston University, Nonlinear Dynamics, NetApp, Duke Institute for Genome Sciences and Policy, Pharsight, InforSense, CLC Bio, J. Craig Venter Institute

Premium
Tripos Signs Deal with AstraZeneca on Molecular Invention Workflow
 
Tripos International said this week that it is developing a drug discovery workflow solution for AstraZeneca. Financial details of the agreement were not made public.
 
The project will be based on Muse, a de novo design product that Tripos plans to release later this year as part of its Pantheon computer-aided drug design platform. Muse will be designed to accelerate the identification and optimization of lead candidates, by combining de novo drug design with “multi-criteria optimization” according to a statement. 
 
"It's important to consider multiple parameters when defining the characteristics of a successful lead or drug candidate. For example, during the lead identification and optimization processes, factors including biological potency and selectivity and ADME properties must be considered.” James Empfield, director of lead optimization chemistry at AstraZeneca, said in a statement. “We look forward to enhancing these capabilities through our collaboration with Tripos."
 
Muse will let researchers find structures, scaffolds, or side-chains that meet specific design objectives and it will be integrated with other molecular design software, the company said. Modelers will be able to generate ideas for chemical structures, and, for example, invent new scaffolds.
 

 
WorldFusion to Become Ariadne Distributor
 
Ariadne said this week that World Fusion is its exclusive distributor in Japan, and will serve as a support center for its MedScan technology and Pathway Studio product line.
 
Pathway Studio, which is powered by MedScan technology, is set up to let scientists organize information and to help them prepare grant and IND applications, plan experimental series, and then analyze and interpret experimental results.
 
Ariadne President Ilya Mazo said that the company has been using World Fusion to market its products to biotechnology and pharmaceutical companies for more than four years.
 

 
Boston University Picks Nonlinear Dynamics’ Progenesis Analysis Software
 
Newcastle upon Tyne, UK -based Nonlinear Dynamics said this week that Boston University’s Cardiovascular Proteomics Center Core Laboratory has chosen its Progenesis software range for label-free LC-MS and 2D gel data analyses.
 
The software gives users an accelerated and visual approach for label-free, quantitative LC-MS analysis, the company said. The CPC Core Laboratory at Boston University had early access to the technology and collaborated on the final development stages to help fine-tune the finished product.
 
The alignment algorithm behind Progenesis was initially developed for 2D gel analysis, the company said, but it “undergone significant development” so it can be applied to LC-MS data analysis.
 
It can also do peak modeling, which reduces the data sets while retaining the relevant quantitation and positional information.
 
“As part of our bioinformatics platform, we have adopted Progenesis LC-MS and Progenesis SameSpots because they offer a powerful and sensitive means to identify changes in label-free, quantitative experiments,” Mark McComb, director of the CPC Core Laboratory, said in a statement. “Furthermore the software is particularly well designed, such that we may easily train our collaborative groups to interrogate their own data and mine more adequately for low-level changes thus increasing the likelihood of discovering novel findings.”
 
No financial details of the deal were disclosed.
 

 
Duke Institute for Genome Sciences and Policy Taps NetApp Deduplication
 
NetApp said this week that the Duke Institute for Genome Sciences and Policy is “dramatically’ reducing its storage capacity genomic information through NetApp deduplication, and thus helping to decrease overall hardware, power, and administration requirements.
 
NetApp can be used across many applications, including primary data, backup data, and archival data, the company said.
 
IGSP's data storage infrastructure has grown from 4 TB to 300 TB within a two-year span with much information contained in Oracle databases on dedicated servers and locally attached storage. As database administrator Rob Wagner said in a statement, the institute was finding that “very difficult to manage.”
 
As part of a server virtualization project, Duke collapsed 40 physical servers down to just three for the Oracle applications. In conjunction with this project, IGSP also made the transition from locally attached storage to consolidated, network-attached NetApp FAS systems.
 
The IGSP environment consists of a 40-node compute farm, three VMware ESX servers, and 50 mixed-use application servers with all data provisioned from a NetApp FAS3070 clustered storage system.
 
"Previously, I spent more time managing 60 TB to 70 TB of direct-attached storage than I do managing the 225 TB of NetApp storage we have now," Alan Cowles, IGSP system administrator, said in a statement.
 

 
Pharsight and InforSense Establish Strategic Partnership
 
Pharsight, a consulting company and software provider in the drug development space, and InforSense have announced a collaboration through which InforSense will distribute Pharsight products in China through its Shanghai-based subsidiary.
 
As part of the agreement, InforSense will represent Pharsight's software for pharmacokinetic and pharmacodynamic analysis, reporting, archiving, and data visualization.
 
Beyond the scope of this agreement, Pharsight and InforSense have also initiated a strategic partnership to deliver translational research solutions to the pharmaceutical industry. The strategic partnership includes opportunities for product-based collaborations to utilize biomarkers in clinical PK/PD modeling.
 
Financial details were not disclosed.
 

 
CLC Bio Lands Agreement with J. Craig Venter Institute
 
CLC Bio said this week that the J. Craig Venter Institute has taken a multi-year site license for the entire CLC bio bioinformatics suite.
 
JCVI will deploy the software across all of its research sites as part of the deal.
 
"JCVI will benefit from implementing this enterprise solution, as it is a full enterprise platform that integrates, supports, and enhances workflows across different technologies and geographical sites,” said Granger Sutton, senior director of Informatics at JCVI.
 
“CLC Bio's software platform impressed our evaluators with its advanced features and intuitive, user-friendly interface," Sutton said.
 
Financial terms of the deal were not disclosed.
 

 
Gene Logic and deSciner Creating Interactive Genomics Resource
 
Gene Logic and deSciner Business Network said this week that they are creating an interactive genomics information resource called Genomics Gateway.
 
The Genomics Gateway will be an interactive forum that includes input from genomic scientists, webinars, interviews, and blogs, among other vehicles. It will be featured on new sections on deSciner’s OBBeC Biotech portal and Gene Logic’s "thought leadership forum."
 
No further details of the alliance were provided.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.